The FDA’s approval of Cimzia for active psoriatic arthritis is based on data from the RAPID-PsA study, an ongoing, Phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of certolizumab pegol in patients (n=409) with active and progressive adult onset psoriatic arthritis.
Patients treated with Cimzia 200mg every other week demonstrated greater reduction in radiographic progression compared with placebo-treated patients at Week 24, as measured by change from baseline in total modified mTSS Score. Also, treatment with Cimzia resulted in improvement in skin manifestations in patients with PsA.
Cimzia is a tumor necrosis factor (TNF) blocker currently approved for the treatment of adults with moderately to severely active rheumatoid arthritis, and in moderately to severely active Crohn’s disease to reduce signs and symptoms and to maintain clinical response in adult patients with inadequate response to conventional therapy.
For more information call (866) 424-6942 or visit Cimzia.com.